bioRxivNeurosciencePreprint
The Alzheimer's disease risk factor APOE4 drives pro-inflammation in human astrocytes via HDAC-dependent repression of TAGLN3
Laurie ArnaudiD, Philippe D. Benech, Louise GreethamiD, Delphine StephaniD, Angélique Jimenez, Nicolas D. JullieniD, Laura García‐GonzáleziD, Philipp O. TsvetkoviD, François DevrediD, Ignacio Sancho-MartineziD, Juan-Carlos Izpisua Belmonte, Kévin BarangeriD, Santiago RiveraiD, Emmanuel NivetiD
Abstract
The Apolipoprotein E4 (APOE4) is the major allelic risk factor for late-onset Alzheimers disease (AD). APOE4 associates with a pro-inflammatory phenotype increasingly considered as critical in AD initiation and progression. Yet, the mechanisms driving an APOE4-dependent neuroinflammation remain unelucidated. Leveraging patient specific human induced Pluripotent Stem Cells (iPSCs) we demonstrate inflammatory chronicity and hyperactivated responses upon cytokines in human APOE4 astrocytes via a novel mechanism. We uncovered that APOE4 represses Transgelin 3 (TAGLN3), a new interacting partner of I{kappa}B, thus increasing the NF-kB activity. The transcriptional repression of TAGLN3 was shown to result from an APOE4-dependent histone deacetylase (HDAC) activity. The functional relevance of TAGLN3 was demonstrated by the attenuation of APOE4-driven neuroinflammation after TAGLN3 supplementation. Importantly, TAGLN3 downregulation was confirmed in the brain of AD patients. Our findings highlight the APOE4-TAGLN3 axis as a new pathogenic pathway that paves the way for the development of therapeutics to prevent maladaptive inflammatory responses in APOE4 carriers, while placing TAGLN3 downregulation as a potential biomarker of AD. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=98 HEIGHT=200 SRC="FIGDIR/small/440108v1_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@1036557org.highwire.dtl.DTLVardef@1f245bdorg.highwire.dtl.DTLVardef@c07c4aorg.highwire.dtl.DTLVardef@1200396_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: statistical model
- approach: experimental assay
- Citations
- 5
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Upregulated NF-κB pathway proteins may underlie APOE4 associated astrocyte phenotypes in sporadic Alzheimer's disease
A. Pryce Roberts, K. Dec, … J. Williams·bioRxiv·Apr 19, 2023
- ApoE4 drives maladaptive heterogeneity and immunometabolic responses of astrocytes
Sangderk Lee, Holden C. Williams, … Josh M. Morganti·bioRxiv·Feb 6, 2023
- Neuronal APOE4 alone is sufficient to drive tau pathology, neurodegeneration, and neuroinflammation in an Alzheimer's disease mouse model
Jessica R. Blumenfeld, Yaqiao Li, … Yadong Huang·bioRxiv·Nov 25, 2025
- Neuronal APOE4 reduction with an APOE-I3-targeting ASO protects against neurodegeneration and neuroinflammation in an Alzheimer's disease mouse model
Oscar Yip, Leon Yao, … Yadong Huang·bioRxiv·Dec 13, 2025
- Inhibiting the cholesterol storage enzyme ACAT1/SOAT1 in aging Apolipoprotein E4 mice alter their brains inflammatory profiles
Thao Nguyen Thanh Huynh, Emma N. Fikse, … Ta‐Yuan Chang·International Journal of Molecular SciencesPeer-reviewed·Dec 21, 2024
- APOE 4/4 promotes dysfunctional and inflammatory phenotypes concomitant with impaired maturation of hiPSC-derived astrocytes
Rebeca Vecino, Eva Díaz‐Guerra, … Carlos Vicario‐Abejón·bioRxiv·Sep 10, 2026